CN109999030A - 牛磺熊去氧胆酸用于治疗神经退行性疾病的用途 - Google Patents

牛磺熊去氧胆酸用于治疗神经退行性疾病的用途 Download PDF

Info

Publication number
CN109999030A
CN109999030A CN201910097334.8A CN201910097334A CN109999030A CN 109999030 A CN109999030 A CN 109999030A CN 201910097334 A CN201910097334 A CN 201910097334A CN 109999030 A CN109999030 A CN 109999030A
Authority
CN
China
Prior art keywords
cholic acid
purposes according
ursodesoxy cholic
tauro ursodesoxy
tudca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910097334.8A
Other languages
English (en)
Chinese (zh)
Inventor
G·里纳尔迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRUSCHETTINI Srl
Original Assignee
BRUSCHETTINI Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48949193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109999030(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BRUSCHETTINI Srl filed Critical BRUSCHETTINI Srl
Priority to CN201910097334.8A priority Critical patent/CN109999030A/zh
Publication of CN109999030A publication Critical patent/CN109999030A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201910097334.8A 2013-07-01 2013-07-01 牛磺熊去氧胆酸用于治疗神经退行性疾病的用途 Pending CN109999030A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910097334.8A CN109999030A (zh) 2013-07-01 2013-07-01 牛磺熊去氧胆酸用于治疗神经退行性疾病的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910097334.8A CN109999030A (zh) 2013-07-01 2013-07-01 牛磺熊去氧胆酸用于治疗神经退行性疾病的用途
PCT/IB2013/055383 WO2015001379A1 (en) 2013-07-01 2013-07-01 Tauroursodeoxycholic acid (tudca) for use in the treatment of neurodegenerative disorders
CN201380077879.3A CN105358147A (zh) 2013-07-01 2013-07-01 牛磺熊去氧胆酸（tudca）用于治疗神经退行性疾病的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380077879.3A Division CN105358147A (zh) 2013-07-01 2013-07-01 牛磺熊去氧胆酸（tudca）用于治疗神经退行性疾病的用途

Publications (1)

Publication Number Publication Date
CN109999030A true CN109999030A (zh) 2019-07-12

Family

ID=48949193

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910097334.8A Pending CN109999030A (zh) 2013-07-01 2013-07-01 牛磺熊去氧胆酸用于治疗神经退行性疾病的用途
CN201380077879.3A Pending CN105358147A (zh) 2013-07-01 2013-07-01 牛磺熊去氧胆酸（tudca）用于治疗神经退行性疾病的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380077879.3A Pending CN105358147A (zh) 2013-07-01 2013-07-01 牛磺熊去氧胆酸（tudca）用于治疗神经退行性疾病的用途

Country Status (16)

Country Link
EP (1) EP3016654B2 (sr)
CN (2) CN109999030A (sr)
CY (1) CY1120835T1 (sr)
DK (1) DK3016654T3 (sr)
ES (1) ES2691408T5 (sr)
HR (1) HRP20181554T4 (sr)
HU (1) HUE040027T2 (sr)
LT (1) LT3016654T (sr)
PL (1) PL3016654T5 (sr)
PT (1) PT3016654T (sr)
RS (1) RS57763B1 (sr)
RU (1) RU2016102092A (sr)
SI (1) SI3016654T2 (sr)
SM (1) SMT201800533T1 (sr)
TR (1) TR201815345T4 (sr)
WO (1) WO2015001379A1 (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
IL293907A (en) * 2019-12-16 2022-08-01 Amylyx Pharmaceuticals Inc Treatment of amyotrophic lateral sclerosis and related disorders
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
JP7701931B2 (ja) * 2020-02-13 2025-07-02 プリレニア ニューロセラピューティクス リミテッド プリドピジンおよび他の活性薬剤を使用して筋萎縮性側索を治療するための併用療法
CN112972480A (zh) * 2021-03-09 2021-06-18 兆科药业（广州）有限公司 一种含牛磺熊去氧胆酸、苯丁酸钠的复方散剂/颗粒剂、制备方法、用途以及其药物组合物
US12138272B2 (en) 2022-05-12 2024-11-12 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
CN120659782A (zh) * 2023-02-15 2025-09-16 深圳君圣泰生物技术有限公司 小檗碱牛磺熊去氧胆酸盐组合物及其方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005289415A1 (en) * 2004-09-24 2006-04-06 Rfe Pharma Llc Carboxy-amido-triazoles for the localized treatment of ocular diseases
CN101048164A (zh) * 2004-11-01 2007-10-03 柳署弘 降低肌萎缩性侧索硬化中神经变性的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1770975A (zh) * 2003-04-02 2006-05-10 明尼苏达大学评议会 提高细胞生存能力的方法
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
JP2008530100A (ja) 2005-02-10 2008-08-07 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 視覚障害の治療方法
WO2010008860A1 (en) 2008-06-23 2010-01-21 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
EP2422787A1 (en) 2010-08-17 2012-02-29 Neurotec Pharma, S.L. Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005289415A1 (en) * 2004-09-24 2006-04-06 Rfe Pharma Llc Carboxy-amido-triazoles for the localized treatment of ocular diseases
CN101048164A (zh) * 2004-11-01 2007-10-03 柳署弘 降低肌萎缩性侧索硬化中神经变性的方法和组合物

Also Published As

Publication number Publication date
RU2016102092A (ru) 2017-08-04
EP3016654A1 (en) 2016-05-11
ES2691408T5 (en) 2026-02-11
HRP20181554T1 (hr) 2018-12-14
EP3016654B2 (en) 2025-11-12
RS57763B1 (sr) 2018-12-31
WO2015001379A1 (en) 2015-01-08
PL3016654T3 (pl) 2019-02-28
CY1120835T1 (el) 2019-12-11
PL3016654T5 (pl) 2026-02-09
SI3016654T2 (sl) 2026-01-30
LT3016654T (lt) 2018-11-12
DK3016654T3 (en) 2018-11-05
PT3016654T (pt) 2018-11-09
HUE040027T2 (hu) 2019-02-28
ES2691408T3 (es) 2018-11-27
SI3016654T1 (sl) 2019-05-31
SMT201800533T1 (it) 2018-11-09
HRP20181554T4 (hr) 2026-03-27
CN105358147A (zh) 2016-02-24
TR201815345T4 (tr) 2018-11-21
EP3016654B1 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
US20240382436A1 (en) Application of r-ketamine and salt thereof as pharmaceuticals
DK3016654T3 (en) TAUROURODEOXYCHOLIC ACID (TUDCA) FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS
JP2019518730A (ja) 眼の炎症性障害および疾患の組合せ処置
Jung et al. The effects of two non-steroidal anti-inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery
Nguyen et al. Dry eye disease: A review of anti-inflammatory therapies
US20140243422A1 (en) Methods of treating behavioral and psychiatric disorders
US10548887B2 (en) Pharmaceutical composition and uses thereof
JP2018502898A (ja) 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現
Lambert et al. Oral delivery of a synthetic sterol reduces axonopathy and inflammation in a rodent model of glaucoma
JP2023539426A (ja) グリコール酸とｌ－アラニンの薬学的組み合わせについて
JP7816716B2 (ja) 強膜菲薄化治療用点眼剤及び強膜菲薄化治療剤のスクリーニング方法
JP2005082523A (ja) 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬
US20240058308A1 (en) Treatment and prevention of dry macular degeneration
WO2021205402A1 (en) Endoxifen for the treatment of bipolar i disorder
Numaga Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients
Simmons 5-Ht1f receptor agonism for the treatment of spinal cord injury
Sant'Ana et al. Effect of Budesonide Nasal Irrigation in Patients With Chronic Rhinosinusitis With Nasal Polyps Without Prior Sinus Surgery: A Randomized, Double‐Blind, Placebo‐Controlled Study
WO2024240216A9 (zh) 一种有效延缓及治疗近视的药物组合物
Wei et al. Lanosterol Fails to Restore Lens Transparency in Murine Cataract: In Vivo and In Vitro Evidence
WO2021205403A1 (en) Endoxifen for the treatment of bipolar i disorder
Chao Investigation on Alternative Treatment Approaches in the Unilateral 6-OHDA Lesion Rat Model of Parkinson's Disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190712